DBV Technologies
$ 13.48
-1.89%
07 Aug - close price
- Market Cap 863,501,000 USD
- Current Price $ 13.48
- High / Low $ 14.09 / 13.30
- Stock P/E N/A
- Book Value 2.71
- EPS -3.36
- Next Earning Report 2026-10-28
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.61 %
- ROE -1.43 %
- 52 Week High 26.18
- 52 Week Low 8.70
About
DBV Technologies SA, a clinical-stage biopharmaceutical company, is dedicated to the research and development of epicutaneous immunotherapy products. The company is headquartered in Montrouge, France.
Analyst Target Price
$41.13
Quarterly Earnings
| Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-07-16 | 2026-04-30 | 2026-03-27 | 2025-10-28 | 2025-07-29 | 2025-04-30 | 2025-03-27 | 2024-11-06 | 2024-07-30 | 2024-05-07 | 2024-03-07 | 2023-10-31 |
| Reported EPS | -0.6 | -0.09 | -0.1994 | -0.21 | -0.27 | -0.23 | -0.2126 | -1.49 | -1.57 | -5.2 | -0.0581 | -1.61 |
| Estimated EPS | -0.12 | -0.12 | -0.1886 | -0.29 | -0.16 | -0.22 | -0.21 | -1.64 | -2.65 | -2.06 | -0.23 | -2.63 |
| Surprise | -0.48 | 0.03 | -0.0108 | 0.08 | -0.11 | -0.01 | -0.0026 | 0.15 | 1.08 | -3.14 | 0.1719 | 1.02 |
| Surprise Percentage | -400% | 25% | -5.7264% | 27.5862% | -68.75% | -4.5455% | -1.2381% | 9.1463% | 40.7547% | -152.4272% | 74.7391% | 38.7833% |
Next Quarterly Earnings
| Sep 2026 | |
|---|---|
| Reported Date | 2026-10-28 |
| Fiscal Date Ending | 2026-09-30 |
| Estimated EPS | -0.15 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: DBVT
2026-08-07 02:09:32
RA Capital Management, L.P., along with Peter Kolchinsky, Rajeev Shah, and RA Capital Healthcare Fund, L.P., has reported a 5.8% beneficial ownership in DBV Technologies S.A. The group collectively owns 18,288,220 ordinary shares, held through 3,657,644 American Depositary Shares (ADSs), with each ADS representing five ordinary shares. This stake was acquired partly through an at-the-market offering on July 30, 2026.
2026-08-06 14:09:32
Arrowstreet Capital has reported a 0.6% net short position in DBV Technologies. This news brief was generated by Public Technologies (PUBT) using AI, based on original content published by DBV Technologies SA. The information provided is for informational purposes only and should not be considered financial advice.
2026-08-05 12:24:00
DBV Technologies stock gained 2.42% to €2.37, ranking among the strongest gains of the SBF 120, despite being down nearly 18% over one month and more than 29% over three months. The stock's rebound from its €2.31 support level and an RSI of 29 indicate an oversold configuration. Three funds still hold significant short positions on the capital, and the company has a $150 million ATM program for ongoing fundraising.
2026-07-31 20:39:08
DBV Technologies' Chief Medical Officer, Mohideen Pharis, sold 464 ordinary shares at $2.70 per share on July 29, 2026. This transaction was executed to cover withholding tax obligations arising from the vesting of restricted stock units. After the sale, Pharis directly holds 144,531 ordinary shares.
2026-07-31 11:39:09
DBV Technologies, a biopharmaceutical company, is positioned for a potential revenue-generating commercial model with its Viaskin Peanut immunotherapy patch for pediatric peanut allergy. Analysts project significant revenue growth and a shift to profitability, driven by a stable addressable market and ongoing clinical program expansion. However, risks include regulatory delays, slower-than-expected market adoption, product concentration, and potential safety or adherence issues in younger patient groups.
2026-07-30 22:11:05
DBV Technologies has successfully raised $50 million through an At-The-Market (ATM) offering of American Depositary Shares (ADS) on Nasdaq. This funding, achieved by issuing 3.66 million ADS at $13.67 each, will bolster the company's financial standing and support the advanced development of its VIASKIN® platform for food allergy treatments. The issuance is expected to conclude by August 3, 2026, and will result in approximately 5.82% dilution for existing shareholders.
